Health-Related Quality of Life in Multidrug Resistant Tuberculosis Patients in Kaduna State, North-Western Nigeria: Comparisons among community and facility model of management
DOI:
https://doi.org/10.60787/tnhj.v22i4.633Keywords:
MDR –TB, Community, Facility, models, comparative, QOLAbstract
Background: The community management of the drug resistant tuberculosis (MDR-TB) was introduced after several years of absolute facility model of care to reduce the logistic and social problems associated with hospital admissions of the MDR-TB patients. This study compares the health-related Quality of life (HRQOL) of patients receiving facility and community-based model of care.
Methods: This was a mixed methods design combining a quantitative cross-sectional survey, a focus group discussion and in-depth interviews with DR TB stakeholders. The study was conducted among 62 MDR TB patients who were managed for MDR TB in Kaduna State from January – June 2022. The QOL data were collected with the modified 36-item short-form (SF-36). Statistical significance was set at p<0.05
Result: The total quality of life (TQL) was 69.14+16.29. The facility mean QOL for role limitation, RL (88.89+8.54), Role emotional, RE (88.89+8.54) and social functioning SF (81.25+7.62) were significantly higher compared to the community model with RL (56.48+7.13) RE (58.03+7.88) and SF(67.69+3.79) The physical component scores (95%CI =62.99-74.47) and the Mental Component scores (95% CI=63.64-75.42) were significantly higher in the facility compared to the community-based care. The FGDs and KII revealed that challenges with training for health care providers, poor supportive supervision and support for home visits were factors affecting community model of MDR-TB.
Conclusion: The patients managed at the facility had a better QOL than those at the community. There is a need for programmatic interventions to address the risk factors for poorer quality of life for the community model.
Downloads
References
CChakaya J, Khan M, Ntoumi F, Aklillu E, Fatima R, Mwaba P, Kapata N, Mfinanga S, Hasnain SE, Katoto PD, Bulabula AN. Global Tuberculosis Report 2020–Reflections on the Global TB burden, treatment and prevention efforts. International Journal of Infectious Diseases. 2021; 113:7-12.
Wells CD, Gupta R, Hittel N, Geiter LJ. Long-term mortality assessment of multidrug-resistant tuberculosis patients treated with delamanid. European Respiratory Journal. 2015 May 1;45(5):1498-501.
Prasad R, Gupta N, Banka A. Multidrug-resistant tuberculosis/rifampicin-resistant tuberculosis: Principles of management. Lung India: official organ of Indian chest society. 2018;35(1):78.
Olawoye IB, Uwanibe JN, Kunle-Ope CN, Davies-Bolorunduro OF, Abiodun TA, Audu RA, Salako BL, Happi CT. Whole genome sequencing of clinical samples reveals extensively drug resistant tuberculosis (XDR TB) strains from the Beijing lineage in Nigeria, West Africa. Scientific reports. 2021 Aug 30;11(1):1-8.
Oladimeji O, Ushie BA, Udoh EE, Oladimeji KE, Ige OM, Obasanya O, et al. Psychosocial wellbeing of patients with multidrug resistant tuberculosis voluntarily confined to long-term hospitalisation in Nigeria. BMJ global health. 2016;1(3):e000006.
Ho J, Byrne AL, Linh NN, Jaramillo E, Fox GJ. Decentralized care for multidrug-resistant tuberculosis: a systematic review and meta-analysis. Bulletin of the World Health Organization. 2017 Aug 8;95(8):584.
Trébucq A, Schwoebel V, Kashongwe Z, Bakayoko A, Kuaban C, Noeske J, Hassane S, Souleymane B, Piubello A, Ciza F, Fikouma V. Treatment outcome with a short multidrug-resistant tuberculosis regimen in nine African countries. The International Journal of Tuberculosis and Lung Disease. 2018 Jan 1;22(1):17-25
Falzon D, Schünemann HJ, Harausz E, González-Angulo L, Lienhardt C, Jaramillo E, Weyer K. World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update. Eur Respir J. 2017;49(3):1602308. doi: 10.1183/13993003.02308-2016.
Williams AO, Makinde OA, Ojo M. Community-based management versus traditional hospitalization in treatment of drug-resistant tuberculosis: a systematic review and meta-analysis. Global health research and policy. 2016 Dec;1(1):1-4.
Uzma Khan, Ismat Lotia-Farrukh, Ahwaz Akhtar, Saira N Khowaja, Salman Khan, Falak Madhani, Asra Parekh, Sana Adnan, Saman Ahmed, Mariam Chaudhry, Hamidah Hussain, Ali Habib, Shahid Butt, Muhammad R Siddiqui, Raafia Ijaz, Saba Jamal, Abdul B Khan, Salmaan Keshavjee, Aamir J Khan, Naseem Salahuddin, Palwasha Y Khan, Re-evaluating the merits of decentralization as a core strategy for effective delivery of drug-resistant tuberculosis care in Pakistan,HealthPolicyandPlanning, 2022; 37(8):979–989.
Deshmukh RD, DhandeDJ, Sachdeva KS, Sreenivas AN, Kumar AM, Parmar M. Social support a key factor for adherence to multidrug-resistant tuberculosis treatment. Indian Journal of Tuberculosis. 2018 Jan 1;65(1):41-7.
Heller T, Lessells RJ, Wallrauch CG, Bärnighausen T, Cooke GS, Mhlongo L, Master I, Newell ML. Community-based treatment for multidrug-resistant tuberculosis in rural KwaZulu-Natal, South Africa. The international journal of tuberculosis and lung disease. 2010 Apr 1;14(4):420-6.
Vaghela JF, Kapoor SK, Kumar A, DassRT, Khanna A, Bhatnagar AK. Home based care to multi-drug resistant tuberculosis patients: a pilot study. Indian Journal of Tuberculosis. 2015 Apr 1;62(2):91-6.
Meressa D, Hurtado RM, Andrews JR, Diro E, Abato K, Daniel T, Prasad P, Prasad R, Fekade B, Tedla Y, Yusuf H. Achieving high treatment success for multidrug-resistant TB in Africa: initiation and scale-up of MDR TB care in Ethiopia—an observational cohort study. Thorax. 2015 Dec 1;70(12):1181-8.
Jaber AA, Ibrahim B. Health-related quality of life of patients with multidrug-resistant tuberculosis in Yemen: prospective study. Health and quality of life outcomes. 2019 Dec;17(1):1-4.
Walker IF, Baral SC, Wei X, Huque R, Khan A, Walley J, Newell JN. Multidrug-resistant tuberculosis treatment programmes insufficiently consider comorbid mental disorders. The International Journal of Tuberculosis and Lung Disease. 2017 Jun 1;21(6):603-9.
Thomas BE, Shanmugam P, Malaisamy M, Ovung S, Suresh C, Subbaraman R, Adinarayanan S, Nagarajan K. Psycho-socio-economic issues challenging multidrug resistant tuberculosis patients: a systematic review. PloS one. 2016 Jan 25;11(1):e0147397.
Cox H, Hughes J, Daniels J, Azevedo V, McDermid C, Poolman M, Boulle A, Goemaere E, Van Cutsem G. Community-based treatment of drug-resistant tuberculosis in Khayelitsha, South Africa. The International Journal of Tuberculosis and Lung Disease. 2014 Apr 1;18(4):441-8.
Bada FO, Okpokoro E, Blok N, Meribole E, Dutt S, Dakum P, Abimiku AL, Zwerling A, Kik SV. Cost of three models of care for drug-resistant tuberculosis patients in Nigeria. BMC Infectious Diseases. 2019 Dec;19(1):1-0.
Oshi D, Chukwu J, Nwafor C, Chukwu NE, Meka AO, Anyim M, Ukwaja KN, Alobu I, Ekeke N, Oshi SN. Support and unmet needs of patients undergoing multidrug‐resistant tuberculosis (MDR‐TB) treatment in southern Nigeria. The International Journal of Health Planning and Management. 2020 Jul;35(4):832-42.
Bieh KL, Weigel R, Smith H. Hospitalized care for MDR-TB in Port Harcourt, Nigeria: a qualitative study. BMC infectiousdiseases. 2017 Dec;17(1):1-9.
Bolarinwa OA. Sample size estimation for health and social science researchers: the principles and considerations for different study designs. Nigerian Postgraduate Medical Journal. 2020 Apr 1;27(2):67-75.
Framework IC. The MOS 36-item short-form health survey (SF-36). Med Care. 1992 Jun;30(6):473-83
Silva SM, Santana AN, Silva NN, Novaes MR. VES-13 and WHOQOL-bref cutoff points to detect quality of life in older adults in primary health care. Revista de Saúde Pública. 2019; 53:26-32.
Sartika I, Insani WN, Abdulah R. Assessment of health-related quality of life among tuberculosis patients in a public primary care facility in Indonesia. Journal of global infectious diseases. 2019;(3):102-106. doi: 10.4103/jgid.jgid_136_18.
Silva PA, Soares SM, Santos JF, Silva LB. Cut-off point for WHOQOL-bref as a measure of quality of life of older adults. Rev Saude Publica. 2014 Jun;48(3):390-7. doi: 10.1590/s0034-8910.2014048004912. PMID: 25119934; PMCID: PMC4203073
Thomas BE, Shanmugam P, Malaisamy M, Ovung S, Suresh C, Subbaraman R, Adinarayanan S, Nagarajan K. Psycho-socio-economic issues challenging multidrug resistant tuberculosis patients: a systematic review. PloS one. 2016 Jan 25;11(1):e0147397.
Deshmukh RD, Dhande DJ, Sachdeva KS, Sreenivas AN, Kumar AM, Parmar M. Social support a key factor for adherence to multidrug-resistant tuberculosis treatment. Indian Journal of Tuberculosis. 2018 Jan 1;65(1):41-7.
Heller T, Lessells RJ, Wallrauch CG, Bärnighausen T, Cooke GS, Mhlongo L, Master I, Newell ML. Community-based treatment for multidrug-resistant tuberculosis in rural KwaZulu-Natal, South Africa. The international journal of tuberculosis and lung disease. 2010 Apr 1;14(4):420-6.
Burtscher D, Juul BjertrupP, Vambe D, Dlamini V, Mmema N, Ngwenya S, Rusch B, Kerschberger B. ‘She is like my mother’: Community-based care of drug-resistant tuberculosis in rural Eswatini. Global Public Health. 2021 Jun 3;16(6):911-23.
Farmer P, Kim JY. Community based approachesto the control of multidrug resistant tuberculosis: introducing “DOTS-plus”. Bmj. 1998 Sep 5;317(7159):671-4.
Thomas BE, Shanmugam P, Malaisamy M, Ovung S, Suresh C, Subbaraman R, Adinarayanan S, Nagarajan K. Psycho-socio-economic issues challenging multidrug resistant tuberculosis patients: a systematic review. PloS one. 2016;11(1):e0147397.
Downloads
Published
Versions
- 2023-03-16 (2)
- 2023-01-07 (1)
How to Cite
Issue
Section
License
Copyright (c) 2022 Journal and Publisher
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The Journal is owned, published and copyrighted by the Nigerian Medical Association, River state Branch. The copyright of papers published are vested in the journal and the publisher. In line with our open access policy and the Creative Commons Attribution License policy authors are allowed to share their work with an acknowledgement of the work's authorship and initial publication in this journal.
This is an open access journal which means that all content is freely available without charge to the user or his/her institution. Users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles in this journal without asking prior permission from the publisher or the author.
The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations. While the advice and information in this journal are believed to be true and accurate on the date of its going to press, neither the authors, the editors, nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.
TNHJ also supports open access archiving of articles published in the journal after three months of publication. Authors are permitted and encouraged to post their work online (e.g, in institutional repositories or on their website) within the stated period, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access). All requests for permission for open access archiving outside this period should be sent to the editor via email to editor@tnhjph.com.
